Today, a Director at Abiomed (NASDAQ: ABMD), Martin Sutter, sold shares of ABMD for $7.52M.
Following Martin Sutter’s last ABMD Sell transaction on June 02, 2015, the stock climbed by 298.5%. This is Sutter’s first Sell trade following 7 Buy transactions.
See today’s analyst top recommended stocks >>
Based on Abiomed’s latest earnings report for the quarter ending March 31, the company posted quarterly revenue of $174 million and quarterly net profit of $36.85 million. In comparison, last year the company earned revenue of $125 million and had a net profit of $14.9 million. ABMD’s market cap is $15.42B and the company has a P/E ratio of 146.19. The Company has a Price to Book ratio of 23.0499.
Based on 6 analyst ratings, the analyst consensus is Strong Buy with an average price target of $320.00, reflecting a 11.9% upside.
In the last 30 days, insiders have sold $7.52M worth of ABMD shares and purchased $1.74M worth of ABMD shares. The insider sentiment on Abiomed has been positive according to 67 insider trades in the past three months. This sentiment is slightly higher than the average sentiment of company insiders in this sector.
Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
ABIOMED, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It distributes its products under the Impella brand. The company was founded in 1981 and is headquartered in Danvers, MA.
